scholarly journals Results of growth hormone substitution therapy in children with brain tumours

2013 ◽  
Vol 59 (2) ◽  
pp. 19-25
Author(s):  
N A Mazerkina ◽  
S K Gorelyshev ◽  
O G Zheludkova ◽  
S S Ozerov ◽  
G L Kobiakov ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Rate ◽  
Brain Tumours ◽  
Adverse Reactions ◽  
Substitution Therapy ◽  
Gh Therapy ◽  
Hormone Substitution ◽  
Gh Replacement ◽  
Receive Growth Hormone ◽  
Growth Hormone Insufficiency

Aim of the study. To estimate the effectiveness and safety of substitution therapy with growth hormone (GH) in children with various brain tumours. Materials and methods. The study involved 68 patients admitted to N.N. Burdenko Institute of Neurosurgery between 2001 and 2011 including 35 ones with craniopharyngioma, 18 with medulloblastoma, and 15 with germ cell tumours (GCT) in the chiasmosellar region. All patients suffered growth hormone insufficiency and received GH replacement therapy. Their antropometric characteristics (height and growth rate) and IGF-1 levels were measured before, 6 and 12 months after the onset of the treatment. The doses of GH varied from 0.03 to 0.034 mg/kg/day. Results. The substitution therapy with GH resulted in an increase of the growth rate in patients with craniopharyngioma from 2.3±1.6 to 9.4±1.9 cm/year (p<0.001), in those with GCT from 1.2±0.9 to 7.4±2.6 cm/year (p=0.01), and in patients with medulloblastoma from 2.3±1.5 to 6.2±2.6 cm/year (p<0.01). The growth rate in patients treated by spinal irradiation was lower than that in those given no such treatment (6.0±2.3 cm/year and 9.2±2.1 cm/year respectively; p<0.001). The tumour recurred in eight of 35 (23%) patients with craniopharyngioma during GH therapy. The frequency of relapses was not significantly different from that in patients who did not receive growth hormone. Patients with medulloblastoma and GCT did not develop relapses. No adverse reactions to GH therapy were documented in this study.

Issues in the Transition From Childhood to Adult Growth Hormone Therapy

PEDIATRICS ◽  
1999 ◽  
Vol 104 (Supplement_5) ◽  
pp. 1004-1010
Author(s):  
David B. Allen
Keyword(s):  
Growth Hormone ◽  
Replacement Therapy ◽  
Blood Lipid ◽  
Hormone Deficiency ◽  
Late Adolescent ◽  
Gh Therapy ◽  
Gh Treatment ◽  
Beneficial Effects ◽  
Gh Replacement ◽  
Adult Growth

The consequences of severe growth hormone deficiency (GHD) in adults and the beneficial effects of GH replacement therapy are clear. However, the majority of children who have a diagnosis of GHD and who are treated with GH do not have permanent GHD and will not require treatment during adulthood. Several issues must be considered in selecting candidates for adult GH treatment and transitioning their care from pediatrics to adult medicine. Counseling about possible lifelong treatment should focus on children with panhypopituitarism and those with severe isolated GHD that is associated with central nervous system abnormalities. When to terminate growth-promoting GH therapy should be guided by balancing the high cost of late-adolescent treatment with the attainment of reasonable statural goals. Retesting for GH secretion is appropriate for all candidates for adult GH therapy; the GH axis can be tested within weeks after the cessation of treatment, but confirming an emerging adult GHD state with body composition, blood lipid, and quality-of-life assessments may require 1 year or more of observation. Selecting patients for lifelong adult GH replacement therapy will present diagnostic, therapeutic, and ethical problems similar to those in treating childhood GHD. The experience and expertise of pediatric endocrinologists in diagnosing and treating GHD should be offered and used in identifying and transitioning appropriate patients to adult GH therapy.

In Reply: Hypothyroidism After Growth Hormone Therapy

PEDIATRICS ◽  
1973 ◽  
Vol 52 (4) ◽  
pp. 626-626
Author(s):  
Robert L. Rosenfield ◽  
Samuel Refetoff ◽  
Leslie J. DeGroot
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Thyroid Function ◽  
Growth Hormone Therapy ◽  
Free Thyroxine ◽  
Gh Therapy ◽  
Gh Replacement ◽  
Significant Change

Drs. Sack and DeLamater quote our paper as confirming the observation that hypothyroidism develops in growth hormone (GH)-deficient patients upon the institution of GH therapy. This statement is incorrect since no significant change in thyroid function was observed during several months of GH therapy. In fact, our data may be interpreted as indicating that some GH-deficient patients have a state of hypothyroidism undetectable by measurement of serum total and free thyroxine levels prior to the institution of GH replacement.

scholarly journals Growth hormone and the cardiovascular system

2011 ◽  
Vol 57 (4) ◽  
pp. 37-47 ◽  
Author(s):  
N N Volevodz
Keyword(s):  
Growth Hormone ◽  
Special Reference ◽  
Cardiovascular System ◽  
Clinical Studies ◽  
Suppressive Therapy ◽  
Pituitary Insufficiency ◽  
Substitution Therapy ◽  
Hormone Substitution ◽  
Clinical Conditions ◽  
Gh Deficit

This review highlights current concepts of physiological and pathophysiological effects of growth hormone on the heart. The data of international clinical studies concerning the influence of GH deficit and excess on the cardiovascular system are discussed with special reference to such clinical conditions as somatotrophic pituitary insufficiency and acromegaly. Result of analysis of parameters of the cardiovascular system in the patients receiving growth hormone substitution therapy for somatotrophic insufficiency and GH-suppressive therapy of acromegaly are presented

scholarly journals Effects of Growth Hormone Substitution Therapy on Cognitive Functioning in Growth Hormone Deficient Patients: A Functional MRI Study

2006 ◽  
Vol 83 (1) ◽  
pp. 12-19 ◽  
Author(s):  
Lucia I. Arwert ◽  
Dick J. Veltman ◽  
Jan Berend Deijen ◽  
P. Sytze van Dam ◽  
Madeleine L. Drent
Keyword(s):  
Growth Hormone ◽  
Cognitive Functioning ◽  
Functional Mri ◽  
Substitution Therapy ◽  
Hormone Substitution ◽  
Mri Study

Outcomes of Growth Hormone Replacement Therapy in Survivors of Childhood Acute Lymphoblastic Leukemia

2002 ◽  
Vol 20 (13) ◽  
pp. 2959-2964 ◽  
Author(s):  
Wing Leung ◽  
Susan R. Rose ◽  
Yinmei Zhou ◽  
Michael L. Hancock ◽  
Stephen Burstein ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Acute Lymphoblastic Leukemia ◽  
Replacement Therapy ◽  
Adult Height ◽  
Gh Deficiency ◽  
Lymphoblastic Leukemia ◽  
Second Malignancy ◽  
Gh Therapy ◽  
Gh Replacement ◽  
Leukemia Relapse

PURPOSE: Little is known about the long-term efficacy or adverse effects of growth hormone (GH) replacement therapy in survivors of childhood acute lymphoblastic leukemia (ALL) who have GH deficiency. We investigated the adult height of patients who had received GH and estimated their risk of leukemia relapse or development of a second malignancy. PATIENTS AND METHODS: Of 910 patients treated for ALL at a single institution, 47 had received GH replacement therapy. The linear growth of these 47 patients was retrospectively evaluated. Their risk of leukemia relapse or second malignancy was compared with that of survivors who did not undergo GH therapy. RESULTS: The median height SD score at the start of GH therapy had decreased by 1.0 since the time of diagnosis of ALL. After a median duration of 4.5 years of GH therapy, adult height SD scores improved and approached height SD scores at the time of diagnosis of ALL. The median adult height for male patients was 173.2 cm (range, 157 to 191.9 cm), and for female patients, it was 158.1 cm (range, 141 to 168 cm). None of the patients developed adverse effects requiring discontinuation of GH treatment. At the 7-year and 11-year landmarks in continuous hematologic remission, there was no statistical evidence that GH therapy was associated with leukemia relapse or development of a second malignancy. CONCLUSION: This study suggests that GH replacement therapy is safe and efficacious for the correction of GH deficiency in survivors of childhood ALL.

Sign in / Sign up

Export Citation Format

Share Document